Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P473 | DOI: 10.1530/endoabs.56.P473

ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Diabetes complications (72 abstracts)

The effect of glutathione S-transferase M1 and T1 polymorphisms on ascorbic acid plasma levels in diabetic patients

Ana Valente 1, , Manuel Bicho 3, , Ana Carolina Santos 3, , Andreia Matos 3, , Rui Duarte 5 , João F Raposo 5 & Helena S Costa 1,

1Departamento de Alimentação e Nutrição, Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Av. Padre Cruz, 1649-016 Lisboa, Portugal, Lisboa, Portugal; 2Atlântica - Escola Universitária de Ciências Empresariais, Saúde, Tecnologias e Engenharia, Oeiras, Portugal; 3Laboratório de Genética, Instituto de Saúde Ambiental, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; 4Instituto de Investigação Científica Bento da Rocha Cabral, Lisboa, Portugal; 5Associação Protectora dos Diabéticos de Portugal, Lisboa, Portugal; 6REQUIMTE/LAQV, Faculdade de Farmácia da Universidade do Porto, Porto, Portugal.

Introduction: Type 2 diabetes mellitus have been associated with excessive production of reactive oxygen species. Glutathione S-transferase (GST) polymorphisms result in decreased or absent enzyme activity and altered oxidative stress. Meta-analyses have indicated that deletion of either GSTM1 or GSTT1 is associated with a significant increased risk of coronary heart disease. The aim of this study was to evaluated if ascorbic acid (AA) plasma levels differ by GST genotype in diabetic patients with and without angiopathy.

Methods: An observational analytical case-control study in 123 Caucasians type 2 diabetic patients was performed. GI - 65 diabetics with angiopathy, GII - 58 diabetics without angiopathy. Plasma levels of AA were measured by a validated HPLC method. The genotyping of GSTT1 and GSTM1 it was determined simultaneously by PCR-Multiplex technique.

Results: The frequency of GSTM1 and GSTT1 single-null genotypes was 42.9% and 30.8% in group I and 43.9% and 31.0% among in group II. The percentage of diabetics patients who had both GSTM1 and GSTT1 functional genotypes was GI:46.0% and GII:42.9%, who had one of the present genotypes was GI:33.4% and GII:37.5% and who had both null genotypes was GI:20.6% and GII:19.6%. Plasma AA concentrations were lower in those with the GSTT1 null genotype than in those with the GSTT1 functional genotype. GSTM1 null genotypes had higher plasma AA levels than those with functional GSTM1 allele. Suboptimal AA plasma concentrations (<4.93 μmol/L) were more frequent in GSTT1 deletion genotype (76.3%) compared to GSTT1-1 (69.4%). Inversely, the percentage of patients with functional GSTM1 allele (72.1%) was higher than null genotype (67.3%).

Conclusion: Plasmatic levels of AA differ by GSTM1 and GSTT1 polymorphisms in Caucasians diabetic patients with or without angiopathy. The upper and lower regulation of AA plasma levels in subjects with nonfunctional GSTT1 or GSTM1 could be partially understood to compensate the lack of functionality.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.